A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
Launched by BRISTOL-MYERS SQUIBB · Mar 6, 2025
Trial Information
Current as of May 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new medication called Deucravacitinib (BMS-986165) to see how it works in children and teenagers with Juvenile Psoriatic Arthritis (JPsA). The main goals are to check how much of the drug gets into the body, how effective it is at treating the condition, and whether it is safe for young patients. The trial is currently open to participants aged between 6 and 20 years who have been diagnosed with JPsA and have at least three joints affected by arthritis. To qualify, participants must have already tried at least one other treatment for JPsA that didn’t work as well as expected or caused side effects.
If someone is eligible and decides to participate, they will be closely monitored throughout the study. This means they will have regular check-ups to assess how the medication is affecting their condition and to ensure their safety. It’s important to note that the study has specific requirements, such as not allowing participants who have been diagnosed with other types of arthritis or certain eye conditions recently. Overall, this trial aims to find a new treatment option for young people struggling with JPsA, with the hope of improving their quality of life.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA).
- • Participants must have at least three joints that are affected by arthritis.
- • Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems.
- • Exclusion Criteria
- • Participants must not have been diagnosed with JPsA before 5 years of age.
- • Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA,
- • Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months.
- • Other protocol-defined Inclusion/Exclusion criteria apply.
About Bristol Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Plovdiv, , Bulgaria
Olomouc, Olomoucký Kraj, Czechia
València, , Spain
Barcelona, Barcelona [Barcelona], Spain
Praha, Praha 5, Czechia
Firenze, Toscana, Italy
Râmnicu Vâlcea, Vâlcea, Romania
Cuiabá, Mato Grosso, Brazil
Belo Horizonte, Minas Gerais, Brazil
Recife, Pernambuco, Brazil
Porto Alegre, Rio Grande Do Sul, Brazil
Porto Alegre, Rio Grande Do Sul, Brazil
Rio De Janeiro, , Brazil
São Paulo, , Brazil
São Paulo, , Brazil
Plovdiv, , Bulgaria
Sofia, , Bulgaria
Beijing, Beijing, China
Guangzhou, Guangdong, China
Nanjing, Jiangsu, China
Changchun, Jilin, China
Shanghai, Shanghai, China
Hangzhou, Zhejiang, China
Olomouc, Olomoucký Kraj, Czechia
Praha, Praha 5, Czechia
Erlangen, Bayern, Germany
Hamburg, , Germany
Hannover, , Germany
Napoli, Campania, Italy
Firenze, Toscana, Italy
Iasi, Iași, Romania
Râmnicu Vâlcea, Vâlcea, Romania
Barcelona, Barcelona [Barcelona], Spain
Madrid, Madrid, Comunidad De, Spain
València, , Spain
Istanbul Fatih, İstanbul, Turkey
Ankara, , Turkey
Ankara, , Turkey
Istanbul, , Turkey
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Cluj Napoca, Cluj, Romania
Lancaster, California, United States
Austin, Texas, United States
Patients applied
Trial Officials
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported